Bortezomib (BTZ)

[Edit]

PS-341; Velcade; Cytomib

Bortezomib (BTZ)
Bortezomib is the first therapeutic proteasome inhibitor to be tested in humans. The drug is an N-protected dipeptide and can be written as Pyz-Phe-boroLeu, which stands for pyrazinoic acid, phenylalanine and Leucine with a boronic acid instead of a carboxylic acid. Peptides are written N-terminus to C-terminus, and this convention is used here even though the "C-terminus" is a boronic acid instead of a carboxylic acid. Bortezomib is rapidly cleared following intravenous administration. Peak concentrations are reached at about 30 minutes. Drug levels can no longer be measured after an hour. Pharmacodynamics are measured by measuring proteasome inhibition in peripheral blood mononuclear cells. The much greater sensitivity of myeloma cell lines and mantle cell lines to proteasome inhibition compared with normal peripheral blood mononuclear cells and most other cancer cell lines is poorly understood.

Organism species: Pan-species (General)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins CPK684Ge11 BSA Conjugated Bortezomib (BTZ) Immunogen; SDS-PAGE; WB.
CPK684Ge21 OVA Conjugated Bortezomib (BTZ) Immunogen; SDS-PAGE; WB.
Antibodies n/a Monoclonal Antibody to Bortezomib (BTZ) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Bortezomib (BTZ) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Bortezomib (BTZ) CLIA Kit Customized Service Offer
n/a ELISA Kit for Bortezomib (BTZ) ELISA Kit Customized Service Offer